These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 2568651)

  • 41. Interaction between fluoxetine and haloperidol: pharmacokinetic and clinical implications.
    Avenoso A; Spinà E; Campo G; Facciolă G; Ferlito M; Zuccaro P; Perucca E; Caputi AP
    Pharmacol Res; 1997 Apr; 35(4):335-9. PubMed ID: 9264051
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Fluphenazine enanthate and fluphenazine decanoate in the treatment of schizophrenic outpatients: extrapyramidal symptoms and therapeutic effect.
    Chouinard G; Annable L; Ross-Chouinard A
    Am J Psychiatry; 1982 Mar; 139(3):312-8. PubMed ID: 6120655
    [No Abstract]   [Full Text] [Related]  

  • 43. Plasma levels of fluphenazine in patients receiving fluphenazine decanoate. Relationship to clinical response.
    Marder SR; Midha KK; Van Putten T; Aravagiri M; Hawes EM; Hubbard JW; McKay G; Mintz J
    Br J Psychiatry; 1991 May; 158():658-65. PubMed ID: 1860020
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pleural fluid eosinophilia with combined pharmacotherapy.
    Chiles C; van Wattum PJ
    Psychosomatics; 2003; 44(5):436-7. PubMed ID: 12954922
    [No Abstract]   [Full Text] [Related]  

  • 45. Importance of oral glucose tolerance test in patient with schizophrenia.
    Margetić B; Aukst-Margetić B; Badanjak A
    Psychiatr Danub; 2005 Jun; 17(1-2):94-6. PubMed ID: 16395850
    [TBL] [Abstract][Full Text] [Related]  

  • 46. RBC and plasma choline in neuroleptic-treated schizophrenic patients.
    Lawson WB; Jeste DV; Hanin I; Kopp U; Wyatt RJ
    Psychiatry Res; 1989 Jul; 29(1):45-53. PubMed ID: 2570429
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia.
    Möller HJ; Riedel M; Jäger M; Wickelmaier F; Maier W; Kühn KU; Buchkremer G; Heuser I; Klosterkötter J; Gastpar M; Braus DF; Schlösser R; Schneider F; Ohmann C; Riesbeck M; Gaebel W
    Int J Neuropsychopharmacol; 2008 Nov; 11(7):985-97. PubMed ID: 18466670
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Long-acting therapy of schizophrenia.
    Rapisarda V; Bonomo V; Parisi R
    Adv Biochem Psychopharmacol; 1985; 40():25-8. PubMed ID: 4025038
    [No Abstract]   [Full Text] [Related]  

  • 49. [Tardive dystonia--a case report on therapy and metaphylaxis].
    Genz A
    Psychiatr Neurol Med Psychol (Leipz); 1988 May; 40(5):264-8. PubMed ID: 2905065
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Beneficial effects of ondansetron as an adjunct to haloperidol for chronic, treatment-resistant schizophrenia: a double-blind, randomized, placebo-controlled study.
    Zhang ZJ; Kang WH; Li Q; Wang XY; Yao SM; Ma AQ
    Schizophr Res; 2006 Dec; 88(1-3):102-10. PubMed ID: 16959472
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Facial dyskinesia: a 16-year follow-up study.
    McClelland HA; Metcalfe AV; Kerr TA; Dutta D; Watson P
    Br J Psychiatry; 1991 May; 158():691-6. PubMed ID: 1677601
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Potential adverse effects of discontinuing psychotropic drugs. Part 3: Antipsychotic, dopaminergic, and mood-stabilizing drugs.
    Howland RH
    J Psychosoc Nurs Ment Health Serv; 2010 Aug; 48(8):11-4. PubMed ID: 20669865
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Treatment of clozapine-associated tardive dyskinesia.
    Lin CC; Bai YM; Chen JY; Wang YC; Liou YJ
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Feb; 32(2):599-600. PubMed ID: 17920744
    [No Abstract]   [Full Text] [Related]  

  • 54. [Involvement of cytochromeP4503A4 in the metabolism of haloperidol and bromperidol].
    Furukori H
    Nihon Shinkei Seishin Yakurigaku Zasshi; 1998 Feb; 18(1):9-14. PubMed ID: 9592806
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Rational polypharmacy in the bipolar affective disorders.
    Post RM; Ketter TA; Pazzaglia PJ; Denicoff K; George MS; Callahan A; Leverich G; Frye M
    Epilepsy Res Suppl; 1996; 11():153-80. PubMed ID: 9294735
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Clinical and economic approach to evaluation of the effectiveness of moditen-depot and haloperidol decanoate in the maintenance therapy of attack-like schizophrenia].
    Ushakov IuV; Kravchenko NE; Kopeĭko GI; Kalugina LI; Mirzoian MG
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1990; 90(7):99-104. PubMed ID: 1979463
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Plasma alpha-one acid glycoprotein and haloperidol concentrations in schizophrenic patients.
    Jann MW; Crabtree BL; Pitts WM; Lam YW; Carter JG
    Neuropsychobiology; 1997; 36(1):32-6. PubMed ID: 9211442
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Maternal haloperidol therapy associated with dyskinesia in a newborn.
    Collins KO; Comer JB
    Am J Health Syst Pharm; 2003 Nov; 60(21):2253-5. PubMed ID: 14619120
    [No Abstract]   [Full Text] [Related]  

  • 59. Expected incidence of tardive dyskinesia associated with atypical antipsychotics.
    Glazer WM
    J Clin Psychiatry; 2000; 61 Suppl 4():21-6. PubMed ID: 10739327
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Risks versus benefits of different types of long-acting injectable antipsychotics.
    McEvoy JP
    J Clin Psychiatry; 2006; 67 Suppl 5():15-8. PubMed ID: 16822092
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.